Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR

Novae B. Simper, Carol L. Jones, Gregory T. MacLennan, Rodolfo Montironi, Sean R. Williamson, Adeboye O. Osunkoya, Mingsheng Wang, Shaobo Zhang, David Grignon, John Eble, Thu Tran, Lisha Wang, Lee A nn Baldrige, Liang Cheng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Basal cell carcinoma (also referred to as adenoid cystic carcinoma) is a rare tumor of the prostate. Although largely characterized as indolent, poor outcomes have been reported in a considerable fraction of cases. As yet, optimum treatment strategies for this cancer have not been developed. This study investigates protein expression of common or potential molecular therapeutic targets and reports on the clinicopathological features of 9 new cases. We evaluated the expression of ERBB2, KIT, androgen receptor, PTEN, EGFR, ERG, and p53 via immunohistochemistry. We also examined EGFR amplification and TMPRSS2-ERG gene rearrangement by fluorescence in situ hybridization. The mean clinical follow-up was 44 months. We found that basal cell carcinoma behaved aggressively with almost one-half of the cases displaying high-risk pathologic features or local recurrence (44%). One patient died as a result of metastatic disease. The most consistent abnormalities included a loss of PTEN expression (56% of cases) and EGFR overexpression (67% of cases). EGFR overexpression occurred in the absence of gene amplification. The TMPRSS2-ERG rearrangement was not detected in any of the tumors studied, nor was ERG protein positivity identified by immunostaining. In addition, ERBB2, KIT, p53, and androgen receptor expressions were either absent or showed only weak, limited reactivity. Our results suggest that there is a high morbidity associated with this tumor, and more intense follow-up and additional treatment may be indicated. Furthermore, targeted therapies directed against the EGFR and PTEN proteins or their constitutive pathways may be promising for future clinical management.

Original languageEnglish
Pages (from-to)805-812
Number of pages8
JournalHuman Pathology
Volume46
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Basal Cell Carcinoma
Prostate
Androgen Receptors
Neoplasms
PTEN Phosphohydrolase
Adenoid Cystic Carcinoma
Gene Rearrangement
Gene Amplification
Therapeutics
Fluorescence In Situ Hybridization
Proteins
Immunohistochemistry
Morbidity
Recurrence

Keywords

  • Basal cell carcinoma
  • Epidermal growth factor receptor (EGFR)
  • Fluorescence in situ hybridization (FISH)
  • Immunohistochemistry
  • Molecular genetics
  • Phosphate and tensin homolog (PTEN)
  • Prostate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. / Simper, Novae B.; Jones, Carol L.; MacLennan, Gregory T.; Montironi, Rodolfo; Williamson, Sean R.; Osunkoya, Adeboye O.; Wang, Mingsheng; Zhang, Shaobo; Grignon, David; Eble, John; Tran, Thu; Wang, Lisha; Baldrige, Lee A nn; Cheng, Liang.

In: Human Pathology, Vol. 46, No. 6, 01.06.2015, p. 805-812.

Research output: Contribution to journalArticle

Simper, Novae B. ; Jones, Carol L. ; MacLennan, Gregory T. ; Montironi, Rodolfo ; Williamson, Sean R. ; Osunkoya, Adeboye O. ; Wang, Mingsheng ; Zhang, Shaobo ; Grignon, David ; Eble, John ; Tran, Thu ; Wang, Lisha ; Baldrige, Lee A nn ; Cheng, Liang. / Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. In: Human Pathology. 2015 ; Vol. 46, No. 6. pp. 805-812.
@article{8ce1e2fd1140481083ec5bddfef5a320,
title = "Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR",
abstract = "Basal cell carcinoma (also referred to as adenoid cystic carcinoma) is a rare tumor of the prostate. Although largely characterized as indolent, poor outcomes have been reported in a considerable fraction of cases. As yet, optimum treatment strategies for this cancer have not been developed. This study investigates protein expression of common or potential molecular therapeutic targets and reports on the clinicopathological features of 9 new cases. We evaluated the expression of ERBB2, KIT, androgen receptor, PTEN, EGFR, ERG, and p53 via immunohistochemistry. We also examined EGFR amplification and TMPRSS2-ERG gene rearrangement by fluorescence in situ hybridization. The mean clinical follow-up was 44 months. We found that basal cell carcinoma behaved aggressively with almost one-half of the cases displaying high-risk pathologic features or local recurrence (44{\%}). One patient died as a result of metastatic disease. The most consistent abnormalities included a loss of PTEN expression (56{\%} of cases) and EGFR overexpression (67{\%} of cases). EGFR overexpression occurred in the absence of gene amplification. The TMPRSS2-ERG rearrangement was not detected in any of the tumors studied, nor was ERG protein positivity identified by immunostaining. In addition, ERBB2, KIT, p53, and androgen receptor expressions were either absent or showed only weak, limited reactivity. Our results suggest that there is a high morbidity associated with this tumor, and more intense follow-up and additional treatment may be indicated. Furthermore, targeted therapies directed against the EGFR and PTEN proteins or their constitutive pathways may be promising for future clinical management.",
keywords = "Basal cell carcinoma, Epidermal growth factor receptor (EGFR), Fluorescence in situ hybridization (FISH), Immunohistochemistry, Molecular genetics, Phosphate and tensin homolog (PTEN), Prostate",
author = "Simper, {Novae B.} and Jones, {Carol L.} and MacLennan, {Gregory T.} and Rodolfo Montironi and Williamson, {Sean R.} and Osunkoya, {Adeboye O.} and Mingsheng Wang and Shaobo Zhang and David Grignon and John Eble and Thu Tran and Lisha Wang and Baldrige, {Lee A nn} and Liang Cheng",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.humpath.2015.02.004",
language = "English",
volume = "46",
pages = "805--812",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR

AU - Simper, Novae B.

AU - Jones, Carol L.

AU - MacLennan, Gregory T.

AU - Montironi, Rodolfo

AU - Williamson, Sean R.

AU - Osunkoya, Adeboye O.

AU - Wang, Mingsheng

AU - Zhang, Shaobo

AU - Grignon, David

AU - Eble, John

AU - Tran, Thu

AU - Wang, Lisha

AU - Baldrige, Lee A nn

AU - Cheng, Liang

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Basal cell carcinoma (also referred to as adenoid cystic carcinoma) is a rare tumor of the prostate. Although largely characterized as indolent, poor outcomes have been reported in a considerable fraction of cases. As yet, optimum treatment strategies for this cancer have not been developed. This study investigates protein expression of common or potential molecular therapeutic targets and reports on the clinicopathological features of 9 new cases. We evaluated the expression of ERBB2, KIT, androgen receptor, PTEN, EGFR, ERG, and p53 via immunohistochemistry. We also examined EGFR amplification and TMPRSS2-ERG gene rearrangement by fluorescence in situ hybridization. The mean clinical follow-up was 44 months. We found that basal cell carcinoma behaved aggressively with almost one-half of the cases displaying high-risk pathologic features or local recurrence (44%). One patient died as a result of metastatic disease. The most consistent abnormalities included a loss of PTEN expression (56% of cases) and EGFR overexpression (67% of cases). EGFR overexpression occurred in the absence of gene amplification. The TMPRSS2-ERG rearrangement was not detected in any of the tumors studied, nor was ERG protein positivity identified by immunostaining. In addition, ERBB2, KIT, p53, and androgen receptor expressions were either absent or showed only weak, limited reactivity. Our results suggest that there is a high morbidity associated with this tumor, and more intense follow-up and additional treatment may be indicated. Furthermore, targeted therapies directed against the EGFR and PTEN proteins or their constitutive pathways may be promising for future clinical management.

AB - Basal cell carcinoma (also referred to as adenoid cystic carcinoma) is a rare tumor of the prostate. Although largely characterized as indolent, poor outcomes have been reported in a considerable fraction of cases. As yet, optimum treatment strategies for this cancer have not been developed. This study investigates protein expression of common or potential molecular therapeutic targets and reports on the clinicopathological features of 9 new cases. We evaluated the expression of ERBB2, KIT, androgen receptor, PTEN, EGFR, ERG, and p53 via immunohistochemistry. We also examined EGFR amplification and TMPRSS2-ERG gene rearrangement by fluorescence in situ hybridization. The mean clinical follow-up was 44 months. We found that basal cell carcinoma behaved aggressively with almost one-half of the cases displaying high-risk pathologic features or local recurrence (44%). One patient died as a result of metastatic disease. The most consistent abnormalities included a loss of PTEN expression (56% of cases) and EGFR overexpression (67% of cases). EGFR overexpression occurred in the absence of gene amplification. The TMPRSS2-ERG rearrangement was not detected in any of the tumors studied, nor was ERG protein positivity identified by immunostaining. In addition, ERBB2, KIT, p53, and androgen receptor expressions were either absent or showed only weak, limited reactivity. Our results suggest that there is a high morbidity associated with this tumor, and more intense follow-up and additional treatment may be indicated. Furthermore, targeted therapies directed against the EGFR and PTEN proteins or their constitutive pathways may be promising for future clinical management.

KW - Basal cell carcinoma

KW - Epidermal growth factor receptor (EGFR)

KW - Fluorescence in situ hybridization (FISH)

KW - Immunohistochemistry

KW - Molecular genetics

KW - Phosphate and tensin homolog (PTEN)

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=84937965500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937965500&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2015.02.004

DO - 10.1016/j.humpath.2015.02.004

M3 - Article

VL - 46

SP - 805

EP - 812

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -